Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,778 across all filing types
Latest filing 2014-05-06 Regulatory Filings
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Evotec and Eternygen enter collaboration to identify and develop novel metabolic disease therapy
Regulatory Filings Classification · 100% confidence The document is a press release dated May 6, 2014, announcing a drug discovery collaboration between Evotec AG and Eternygen GmbH regarding metabolic disease therapy. It contains standard press release formatting, including contact information, forward-looking statements, and is disseminated via DGAP (a corporate news service). This type of announcement, detailing a strategic partnership or alliance, does not fit the specific definitions for financial reports (10-K, IR, ER), governance documents (CGR, DEF 14A), or shareholder actions (DIV, DVA). It is a general corporate news item detailing business development. Since it is not a formal regulatory filing like a 10-K or a specific financial report, and it is not an announcement of a report publication (RPA), the most appropriate general category for a significant business development announcement that doesn't fit elsewhere is 'Regulatory Filings' (RNS), which serves as a broad category for corporate news releases disseminated through official channels.
2014-05-06 English
Evotec AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is very short (1361 characters) and announces a change in the 'Total Voting Rights' as of April 30, 2014, citing Article 26a of the WpHG. This type of announcement, detailing the total number of shares with voting rights, is a specific regulatory disclosure. It is not a full report (like 10-K or IR), nor is it a dividend announcement (DIV) or a director's dealing (DIRS). It most closely aligns with a general regulatory filing or a specific notification regarding share capital/voting rights. Since there is no specific code for 'Total Voting Rights Announcement', and it is a mandatory regulatory disclosure distributed via DGAP, the most appropriate general category is Regulatory Filings (RNS), as it is a mandatory, non-financial-statement-specific regulatory update.
2014-04-30 English
Evotec receives first milestone in Roche biomarker collaboration
Regulatory Filings Classification · 99% confidence The document is a press release titled "Evotec receives first milestone in Roche biomarker collaboration" disseminated via DGAP-News. It announces a specific operational achievement (milestone achievement in a collaboration) and provides context about the underlying agreement and technology. This type of announcement, which is not a formal periodic report (like 10-K or IR), a specific financial event (like DIV or CAP), or a management change (MANG), falls best under the general category of a corporate news release or regulatory announcement that doesn't fit a more specific financial or governance code. Since it is a specific, non-standard corporate update disseminated through a regulatory news service (DGAP), and it doesn't fit ER, LTR, MANG, or any other specific code, the most appropriate fallback is Regulatory Filings (RNS), which covers general regulatory announcements.
2014-04-24 English
Investor Presentation 2014
Investor Presentation Classification · 99% confidence The document contains detailed financial tables (Umsatz, EBIT, EPS, KGV, EV/Sales, etc.), forward-looking guidance for 2014e and 2015e, strategic updates ('Action Plan 2016'), and a clear investment recommendation ('Kaufen' with a price target of € 4,46) issued by a research firm (getinsight Research GmbH) on April 17, 2014. The content is a comprehensive analysis of the company's performance, strategy, and valuation, typical of an equity research report. This aligns best with the 'Investor Presentation' (IP) category, as it is a detailed analysis intended for investors, although it is not explicitly a presentation slide deck. However, given the options, 'IP' (Investor Presentation) is the closest fit for a detailed, forward-looking equity research document, which often serves the same purpose as an investor presentation in conveying investment theses. It is not a formal regulatory filing like 10-K or IR, nor is it a short announcement (RPA/RNS).
2014-04-17 German
Declaration of Voting Results & Voting Rights Announcements 2014
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and details notifications received from various Morgan Stanley entities regarding changes in their voting rights in Evotec AG, referencing specific German securities law (§ 26 WpHG, Article 21, Section 1). This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes or related voting rights notifications.
2014-04-08 English
Declaration of Voting Results & Voting Rights Announcements 2014
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and details notifications received according to Article 21, Section 1 of the WpHG (German Securities Trading Act) regarding changes in voting rights thresholds (exceeding 3%) held by Morgan Stanley entities in Evotec AG. This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes or related voting rights changes.
2014-04-07 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.